Wealthquest Corp Purchases Shares of 1,923 Krystal Biotech, Inc. (NASDAQ:KRYS)

Key Points

• Wealthquest Corp has invested approximately $347,000 in Krystal Biotech, Inc., acquiring 1,923 shares during the first quarter.
• Multiple institutional investors have increased their stakes in Krystal Biotech, with hedge funds owning 86.29% of the company's stock.
• Krystal Biotech reported earnings of $1.20 per share, missing the consensus estimate of $1.38, and expects to post an EPS of 6.14 for the current year.

Wealthquest Corp purchased a new position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 1,923 shares of the company's stock, valued at approximately $347,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Sound View Wealth Advisors Group LLC increased its stake in Krystal Biotech by 6.7% in the first quarter. Sound View Wealth Advisors Group LLC now owns 1,515 shares of the company's stock valued at $273,000 after purchasing an additional 95 shares during the period. Bryce Point Capital LLC acquired a new position in shares of Krystal Biotech during the first quarter worth about $790,000. Legato Capital Management LLC acquired a new position in shares of Krystal Biotech during the first quarter worth about $936,000. Pier 88 Investment Partners LLC increased its stake in shares of Krystal Biotech by 18.1% during the first quarter. Pier 88 Investment Partners LLC now owns 4,430 shares of the company's stock worth $799,000 after acquiring an additional 680 shares during the period. Finally, Los Angeles Capital Management LLC increased its stake in shares of Krystal Biotech by 152.2% during the first quarter. Los Angeles Capital Management LLC now owns 24,929 shares of the company's stock worth $4,495,000 after acquiring an additional 15,045 shares during the period. 86.29% of the stock is currently owned by institutional investors and hedge funds.

Krystal Biotech Stock Down 13.6%

Shares of KRYS traded down $21.33 during mid-day trading on Monday, reaching $135.65. 1,158,684 shares of the company's stock were exchanged, compared to its average volume of 324,572. The company has a 50-day simple moving average of $140.83 and a two-hundred day simple moving average of $155.89. Krystal Biotech, Inc. has a 52-week low of $122.80 and a 52-week high of $207.84. The company has a market cap of $3.92 billion, a price-to-earnings ratio of 32.43 and a beta of 0.70.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last issued its quarterly earnings data on Monday, August 4th. The company reported $1.29 earnings per share for the quarter, topping analysts' consensus estimates of $1.08 by $0.21. Krystal Biotech had a net margin of 37.17% and a return on equity of 14.64%. The business had revenue of $96.04 million during the quarter, compared to analysts' expectations of $95.42 million. As a group, equities research analysts predict that Krystal Biotech, Inc. will post 6.14 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the stock. HC Wainwright reiterated a "buy" rating and set a $240.00 price target on shares of Krystal Biotech in a research note on Friday, July 25th. Bank of America lowered their target price on shares of Krystal Biotech from $193.00 to $192.00 and set a "buy" rating on the stock in a research report on Tuesday, July 22nd. Guggenheim lowered their target price on shares of Krystal Biotech from $195.00 to $189.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. Chardan Capital restated a "buy" rating and set a $219.00 target price on shares of Krystal Biotech in a research report on Friday, July 25th. Finally, Citigroup restated a "neutral" rating and set a $176.00 target price (up from $155.00) on shares of Krystal Biotech in a research report on Wednesday, July 9th. One research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $211.33.

Insiders Place Their Bets

In other Krystal Biotech news, insider Suma Krishnan sold 13,435 shares of the business's stock in a transaction on Monday, July 14th. The stock was sold at an average price of $150.30, for a total value of $2,019,280.50. Following the completion of the transaction, the insider directly owned 1,443,276 shares in the company, valued at approximately $216,924,382.80. The trade was a 0.92% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In the last three months, insiders sold 49,800 shares of company stock valued at $7,487,943. Insiders own 13.70% of the company's stock.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).